The BET inhibitor pelabresib decreases inflammatory cytokines, improves bone marrow fibrosis and function, and demonstrates clinical response irrespective of mutation status in myelofibrosis patients in the phase 2 MANIFEST trial Meeting Abstract
| Authors: | Zavidij, O.; Keller, P.; Cui, J. K.; Mertz, J.; Salama, M.; Olteanu, H.; Chiu, A.; Chen, D.; Hanson, C. A.; Chen, Z. H.; Verstovsek, S.; Harrison, C.; Mascarenhas, J.; Talpaz, M.; Mesa, R.; Vannucchi, A.; Rampal, R.; Oh, S.; Colak, G.; Luptakova, K.; Humphrey, J.; Wang, J.; Trojer, P. |
| Abstract Title: | The BET inhibitor pelabresib decreases inflammatory cytokines, improves bone marrow fibrosis and function, and demonstrates clinical response irrespective of mutation status in myelofibrosis patients in the phase 2 MANIFEST trial |
| Meeting Title: | 9th Annual Meeting of the Society of Hematologic Oncology (SOHO) |
| Keywords: | myelofibrosis; cytokine; myeloid differentiation; mpn; bone marrow fibrosis; pelabresib |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 21 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2021 Sep 8-11 |
| Meeting Location: | Virtual event |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2021-09-01 |
| Start Page: | S363 |
| End Page: | S364 |
| Language: | English |
| ACCESSION: | WOS:000691910500273 |
| PROVIDER: | wos |
| DOI: | 10.1016/s2152-2650(21)01835-8 |
| Notes: | Meeting Abstract: MPN-343 -- Source: Wos |
